To be certain that an obesity drug does not increase cardiovascular risk would require a superiority trial prior to approval, CDER Deputy Director for Clinical Science Robert Temple told the Endocrinologic and Metabolic Drugs Advisory Committee March 28.
Temple’s comments came during the first of a two-day session to discuss how and when to evaluate the cardiovascular risk...